Amylyx Pharmaceuticals

Quarterly Financials

Values in thousands 2024-09-30 2024-06-30 2024-03-31 2023-12-31
Revenue
$416
$-1,022
$88,643
$108,449
Gross Profit
-393
-8,648
-28,078
99,089
EBITDA
-39,237
-53,227
-121,815
2,235
EBIT
-39,458
-53,435
-122,130
1,934
Net Income
-72,704
-72,700
-118,793
4,731
Net Change In Cash
416
-1,022
88,643
108,449
Free Cash Flow
-41,551
-66,669
-556
13,195
Cash
71,839
74,999
170,552
170,201
Basic Shares
68,091
68,024
67,854
69,196

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$380,786
$22,230
$285
$650
Gross Profit
355,345
19,237
285
-23,944
EBITDA
39,890
-200,854
-82,636
-39,004
EBIT
38,802
-201,341
-82,688
-39,005
Net Income
49,271
-198,375
-87,879
-44,837
Net Change In Cash
380,786
22,230
285
650
Cost of Revenue
12,930
Free Cash Flow
10,678
-182,397
-75,152
-36,848
Cash
170,201
62,526
50,191
12,877
Basic Shares
69,991
66,512
57,864
56,466

Earnings Calls

Quarter EPS
2024-09-30
-$1.07
2024-06-30
-$0.73
2024-03-31
-$0.12
2023-12-31
$0.07